Welcome to our dedicated page for Arteris SEC filings (Ticker: AIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Arteris, Inc.'s SEC filings can feel like navigating a dense wiring diagram—hundreds of pages on deferred royalties, automotive safety certifications, and stock-based compensation. If you need the revenue backlog buried in a 10-K or want to spot Form 4 trades before the next design-win press release, the traditional EDGAR search simply takes too long.
Stock Titan solves this problem. Our AI-powered summaries translate complex semiconductor accounting into plain language, flagging key metrics such as licensing revenue mix, R&D capitalization trends, and customer concentration. Real-time alerts pull every Arteris quarterly earnings report 10-Q filing, 8-K material events explained in minutes, and Arteris insider trading Form 4 transactions as they post—so you never miss a disclosure.
Here’s what you can uncover instantly:
- Arteris annual report 10-K simplified—royalty schedules, risk factors, and segment performance distilled within seconds.
- Arteris Form 4 insider transactions real-time—track executive stock sales or option exercises alongside AI context on upcoming product milestones.
- Proxy statement executive compensation—see how design-win milestones affect equity awards without combing through tables.
- Arteris earnings report filing analysis—compare quarter-over-quarter gross margin shifts and R&D intensity.
Whether you’re monitoring executive stock transactions, assessing patent litigation exposure, or just trying to understand Arteris SEC filings explained simply, our platform surfaces the data professionals rely on—no jargon, no delays.
Arteris, Inc. director Joachim Kunkel reported receipt of
Following the transaction, the reporting person beneficially owns
Arteris, Inc. reported a Form 144 notice for the proposed sale of 5,755 common shares with an aggregate market value of
Arteris, Inc. insider notice reports a proposed sale under Rule 144 of 11,841 common shares with an aggregate market value of
Notice of proposed insider sale: This Form 144 reports a planned sale of 17,200 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of
Arteris, Inc. (AIP) filed a Form 144 reporting a proposed Rule 144 sale of 100,000 common shares through Morgan Stanley Smith Barney LLC on the
The filing also discloses multiple sales by the same person (and related 10b5-1 plans) during the past three months, including a 94,245-share 10b5-1 sale on
Arteris, Inc. filing of Form 144 notifies the market of a proposed sale of 4,750 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $53,485.00. The sale is to occur on or about 10/03/2025 on NASDAQ. The shares were acquired as Restricted Stock Units on 10/01/2025 from the issuer and are listed as 4,750 units in the notice. The filing also discloses multiple recent sales by the same person, Paul Alpern, during the past three months with individual sale dates and proceeds provided.
The form includes the seller's representation that no undisclosed material adverse information is known and provides broker contact details; it documents compliance with Rule 144 sale notice requirements rather than presenting operational or financial performance data.
Arteris, Inc. filed a Form 144 disclosing a proposed sale of 1,554 common shares to be executed through Morgan Stanley Smith Barney LLC on 10/03/2025 on NASDAQ. The filing states these shares were acquired as Restricted Stock Units from the issuer on 10/01/2025 and were paid/settled on the same date. The filing also lists multiple consummated sales by Laurent Moll during the prior three months, including sales of 42,692 shares on 09/02/2025 and other 10b5-1 plan sales totaling tens of thousands of shares across July–October 2025. The company reports 42,649,917 shares outstanding, and the proposed sale represents a small fraction of that total.
Arteris, Inc. (AIP) filed a Form 144 notifying the proposed sale of 11,821 common shares with an aggregate market value of $133,104.46. The shares are to be sold on or about 10/03/2025 on NASDAQ.
The filing shows these shares were acquired as Restricted Stock Units from the issuer on 10/01/2025. The filer reported multiple sales in the prior three months, including sales of 94,245 shares on 08/05/2025 (gross proceeds $1,271,120.01) and other transactions on 09/02/2025, 09/04/2025, and 10/02/2025.
Paul L. Alpern, Vice President and General Counsel of Arteris, Inc. (AIP), reported transactions dated 10/01/2025 executed under a 10b5-1 trading plan adopted on June 5, 2025. The reporting person acquired 5,000 shares (transaction code M) at an effective price of $0.56 and sold 5,000 shares (transaction code S) at a weighted average price of $10.3089, with sale prices ranging from $10.16 to $10.51. After the transactions, the report shows 73,587 shares beneficially owned as to the non-derivative holdings and 85,000 shares when including derivative securities. The derivative shown is an option with a $0.56 exercise price exercisable beginning 10/01/2025 and expiring 10/23/2029. The filing is signed and dated 10/03/2025.
Arteris, Inc. reported a Form 144 notice showing an intended sale of 19,060 shares of its common stock by a holder using Morgan Stanley Smith Barney LLC as broker, with an aggregate market value of $200,130.00. The filing states the shares were acquired as Restricted Stock Units on 09/03/2024 and the planned approximate sale date is 10/02/2025 on NASDAQ. The issuer has 42,649,917 shares outstanding per the filing. The notice also lists multiple recent sales by the same person under a 10b5-1 plan and direct sales between 07/03/2025 and 09/09/2025, totaling tens of thousands of shares and several hundred thousand dollars in gross proceeds.
FAQ
What is the current stock price of Arteris (AIP)?
What is the market cap of Arteris (AIP)?
